Researchers are developing techniques to genetically modify cancer-fighting immune cells directly inside patients rather than in expensive laboratory facilities, potentially making CAR-T therapy accessible to far more people.

Current CAR-T treatments require removing a patient's T cells, shipping them to specialized facilities for genetic engineering, then returning them weeks later at costs around $500,000 per dose. The new "in vivo" approaches use viral vectors or RNA-loaded nanoparticles to deliver genetic instructions directly to T cells circulating in the bloodstream, which could reduce costs by an order of magnitude. Companies including Capstan Therapeutics, co-founded by Nobel laureates, and AstraZeneca-backed EsoBiotec have launched early human trials. While only about 200 US centers currently offer traditional CAR-T therapy, the approach could make the powerful treatment available on demand like conventional drugs.

An anonymous reader quotes a report from Phys.Org: Neuroscientists and materials scientists have created contact lenses that enable infrared vision in both humans and mice by converting infrared light into visible light. Unlike infrared night vision goggles, the contact lenses, described in the journal Cell, do not require a power source -- and they enable the wearer to perceive multiple infrared wavelengths. Because they're transparent, users can see both infrared and visible light simultaneously, though infrared vision was enhanced when participants had their eyes closed. [...] The contact lens technology uses nanoparticles that absorb infrared light and convert it into wavelengths that are visible to mammalian eyes (e.g., electromagnetic radiation in the 400-700 nm range). The nanoparticles specifically enable the detection of "near-infrared light," which is infrared light in the 800-1600 nm range, just beyond what humans can already see.

The team previously showed that these nanoparticles enable infrared vision in mice when injected into the retina, but they wanted to design a less invasive option. To create the contact lenses, the team combined the nanoparticles with flexible, nontoxic polymers that are used in standard soft contact lenses. After showing that the contact lenses were nontoxic, they tested their function in both humans and mice. They found that contact lens-wearing mice displayed behaviors suggesting that they could see infrared wavelengths. For example, when the mice were given the choice of a dark box and an infrared-illuminated box, contact-wearing mice chose the dark box whereas contact-less mice showed no preference. The mice also showed physiological signals of infrared vision: the pupils of contact-wearing mice constricted in the presence of infrared light, and brain imaging revealed that infrared light caused their visual processing centers to light up. In humans, the infrared contact lenses enabled participants to accurately detect flashing morse code-like signals and to perceive the direction of incoming infrared light.

An additional tweak to the contact lenses allows users to differentiate between different spectra of infrared light by engineering the nanoparticles to color-code different infrared wavelengths. For example, infrared wavelengths of 980 nm were converted to blue light, wavelengths of 808 nm were converted to green light, and wavelengths of 1,532 nm were converted to red light. In addition to enabling wearers to perceive more detail within the infrared spectrum, these color-coding nanoparticles could be modified to help color-blind people see wavelengths that they would otherwise be unable to detect. [...] Because the contact lenses have limited ability to capture fine details (due to their close proximity to the retina, which causes the converted light particles to scatter), the team also developed a wearable glass system using the same nanoparticle technology, which enabled participants to perceive higher-resolution infrared information. Currently, the contact lenses are only able to detect infrared radiation projected from an LED light source, but the researchers are working to increase the nanoparticles' sensitivity so that they can detect lower levels of infrared light.

Scientists have successfully treated a 9.5-month-old boy with an ultra-rare genetic disorder using the world's first personalized gene-editing therapy. The patient, identified as KJ, has CPS1 deficiency -- a condition affecting just one in 1.3 million babies that prevents proper ammonia processing and is often fatal.

The breakthrough treatment, detailed in the New England Journal of Medicine, uses base editing technology to correct KJ's specific DNA mutation. The therapy delivers CRISPR components wrapped in fatty lipid molecules that protect them in the bloodstream until they reach liver cells, where they make the precise edit needed.

After three infusions, KJ now eats normal amounts of protein and has maintained stable ammonia levels even through viral illnesses that would typically cause dangerous spikes. His weight has increased from the 7th to 40th percentile. Dr. Peter Marks, former FDA official, called the approach "one of the most potentially transformational technologies" because it could be rapidly adapted for thousands of other rare genetic diseases without lengthy development cycles.

"Using electrochemistry, University of Oregon researchers have developed a way to make iron metal for steel production without burning fossil fuels..." the University of Oregon wrote last year. "Decarbonizing this step would do roughly as much to reduce greenhouse gas emissions as converting every gas-guzzling vehicle on the roads to electric... If scaled up, the process could help decarbonize one of the largest and most emissions-intensive industries worldwide," replacing carbon-spewing industrial blast furnaces.

Paul Kempler, their research assistant chemistry professor, added "The reason we got excited about this chemistry, is that our reactants are two things that are very cheap: saltwater and iron oxide." And this week he announced that "We actually have a chemical principle, a sort of guiding design rule, that will teach us how to identify low-cost iron oxides that we could use in these reactors."

"Those reactions conveniently also produce chlorine, a commercially valuable byproduct," writes SciTechDaily, in a new follow-up report this week: In their latest study, the researchers focused on improving the process by identifying which types of iron oxides make the reaction more cost-effective, an essential step toward scaling the method for industrial use.... In lab tests, the difference was striking: "With the really porous particles, we can make iron really quickly on a small area," Goldman said. "The dense particles just can't achieve the same rate, so we're limited in how much iron we can make per square meter of electrodes...."

To take their process beyond the lab, Kempler's lab is working with researchers in other fields. A collaboration with civil engineers at Oregon State University is helping them better understand what's needed for the product to work in real-world applications. And collaboration with an electrode manufacturing company is helping them address the logistical and scientific challenges of scaling up an electrochemical process. "I think what this work shows is that technology can meet the needs of an industrial society without being environmentally devastating," Goldman said.

"We haven't solved all the problems yet, of course, but I think it's an example that serves as a nucleation point for a different way of thinking about what solutions look like. We can continue to have industry and technology and medicine, and we can do it in a way that's clean — and that's awesome!"

A new study projects that CT scans conducted in 2023 may result in around 103,000 future cancer cases in the U.S. due to low-dose ionizing radiation. "[I]t would put CT scans on par with other significant risk factors for cancer, like alcohol consumption, at least at a population level," reports ScienceAlert. From the report: At an individual level, the theoretical chance of developing cancer from a CT scan is thought to be very minimal, if it exists at all, and patients should not be scared of undergoing these tests if they are deemed medically necessary. However, the number of CT examinations performed each year in the US has increased by more than 30 percent since 2007, and researchers suggest that unwarranted tests are exposing the population to unnecessary radiation. [...]

The anonymous data comes from 143 hospitals and outpatient facilities across the US, catalogued in the UCSF International CT Dose Registry. Using statistics from 2016 to 2022, researchers predicted 93 million CT examinations were carried out in 2023, on roughly 62 million patients. Based on the associated radiation risks, the team estimates that CT scans in 2023 may be tied to 103,000 future cancers. The findings have been published in JAMA Internal Medicine.

Germany will get a new "super-high-tech ministry" responsible for research, technology, and aerospace, according to the coalition agreement published by the incoming government this week. From a report: The announcement is one of several nods to science in the 144-page agreement, unveiled on 9 April following weeks of negotiations between the center-right Christian Democrats (CDU) and its sister party, the Christian Social Union in Bavaria (CSU) -- who together won the most seats in February's federal elections -- and the center-left Social Democrats. The agreement is expected to be formally approved by the three parties by early May, paving the way for CDU leader Friedrich Merz to be elected chancellor.

[...] The new agreement lists a number of scientific priorities for the new government, including support for artificial intelligence, quantum technologies, biotechnology, microchip development and production, and fusion energy. "Our goal is that the world's first fusion reactor should be realized in Germany," the text states. It also mentions personalized medicine, oceans research, and sustainability research as "strategic" areas. But the agreement does not include any budget estimates, and observers caution it is unclear where the money for new programs would come from. The agreement does affirm current commitments to increase the budgets of the country's main research organizations by 3% per year through 2030.

New research suggests that given the right kind of training, AI bots can deliver mental health therapy with as much efficacy as -- or more than -- human clinicians. From a report: The recent study, published in the New England Journal of Medicine, shows results from the first randomized clinical trial for AI therapy. Researchers from Dartmouth College built the bot as a way of taking a new approach to a longstanding problem: The U.S. continues to grapple with an acute shortage of mental health providers. "I think one of the things that doesn't scale well is humans," says Nick Jacobson, a clinical psychologist who was part of this research team. For every 340 people in the U.S., there is just one mental health clinician, according to some estimates.

While many AI bots already on the market claim to offer mental health care, some have dubious results or have even led people to self-harm. More than five years ago, Jacobson and his colleagues began training their AI bot in clinical best practices. The project, says Jacobson, involved much trial and error before it led to quality outcomes. "The effects that we see strongly mirror what you would see in the best evidence-based trials of psychotherapy," says Jacobson. He says these results were comparable to "studies with folks given a gold standard dose of the best treatment we have available."

Scientists "demonstrated a promising step toward using a person's own immune cells to fight gastrointestinal cancers" at America's National Institutes of Health (or NIH), reports the Washington Post.

But the results were published in Nature Medicine on Tuesday — "the same day the agency was hit with devastating layoffs..." The treatment approach is still early in its development; the personalized immunotherapy regimen shrank tumors in only about a quarter of the patients with colon, rectal and other GI cancers enrolled in a clinical trial. But a researcher who was not involved in the study called the results "remarkable" because they highlight a path to a frustratingly elusive goal in medicine — harnessing a person's own immune defenses to target common solid tumor cancers. Until now, cell-based immunotherapy has worked mainly on blood cancers, such as leukemia, but not the solid cancers that seed tumors in the breast, brain, lungs, pancreas and GI tract...

But the progress arrives at a sad time for science — and for patients, said the leader of the work, NIH immunotherapy pioneer Steven Rosenberg. Two patients' treatments using the experimental therapy had to be delayed because NIH's capacity to make personalized cell therapies has been slowed by the firing of highly skilled staff and by purchasing slowdowns. Those occurred even before major layoffs took place Tuesday... The Department of Health and Human Services (HHS) responded to an email asking about clinical trial delays with a statement: "NIH and HHS are complying with President Trump's executive order."
It's "a very exciting study," said Patrick Hwu, president of the Moffitt Cancer Center in Tampa. Finding ways to tailor this cell-based immunotherapy approach to common solid tumors that cause the vast majority of cancer deaths has remained a major scientific challenge... Rosenberg and colleagues first tried to create tumor infiltrating lymphocytes [or "TILs"] using the method that worked in melanoma for 18 patients with GI cancers that had spread. It failed completely. In a second iteration, his team sequenced the mutations present in each patient's tumor and used that information to sift out and expand the TILs that could home in on that patient's specific tumor cells. The results were far from a triumph, but provided a clue — this time, three of 39 patients' tumors shrank. In the last stage of the trial, the scientists added a drug called pembrolizumab that takes the brakes off immune cells. This time, eight of the 34 patients responded.

"Right now, only a few labs in the country can do what they just did," Hwu said.
While Rosenberg is already working "to refine and improve upon the results," he told the Post that two scientists involved in the specialized process of preparing the cells to treat patients were fired in the probationary purge. "We've had to slow down our work and delay the treatment of some patients...."

And there's also dramatically fewer people now who can purchase research materials, which the Post says it "making it slower and more difficult to obtain supplies."

"U.S. stock market futures plunged on Sunday evening," reports Yahoo Finance, "after the new U.S. tariff policy began collecting duties over the weekend..."

The EU will vote on $28 billion in retaliatory tariffs Wednesday, Reuters reports. (And those tariffs will be approved unless "a qualified majority of 15 EU members representing 65% of the EU's population oppose it. They would enter force in two stages, a smaller part on April 15 and the rest a month later.")

But France's Economy and Finance Minister has an idea: more strictly regulating how data is used by America's Big Tech companies. Politico EU reports/A>: "We may strengthen certain administrative requirements or regulate the use of data," Lombard said in an interview with Le Journal Du Dimanche. He added that another option could be to "tax certain activities," without being more specific.

A French government spokesperson already said last week that the EU's retaliation against U.S. tariffs could include "digital services that are currently not taxed." That suggestion was fiercely rejected by Ireland, which hosts the European headquarters of several U.S. Big Tech firms...

Technology is seen as a possible area for Europe to retaliate. The European Union has a €157 billion trade surplus in goods, which means it exports more than it imports, but it runs a deficit of €109 billion in services, including digital services. Big Tech giants like Apple, Microsoft, Amazon, Google and Meta dominate many parts of the market in Europe.
Amid the market turmoil, what about cryptocurrencies, often seen as a "proxy" for the level of risk felt by investors? In the 10 weeks after October 6, the price of Bitcoin skyrocketed 67% to $106,490 by December 10th. But by January 30th it had started dropping again, and now sits at $77,831 — still up 22% for the last six months, but down nearly 27% over the last 10 weeks. Yet even after all that volatility, Bitcoin suddenly fell again more than 6% on Sunday, reports Reuters, "as markets plunged amid tariff tensions. Ether, the second largest cryptocurrency, fell more than 10% on Sunday."

An anonymous reader quotes a report from Ars Technica: [...] The study, led by researchers at Brown University, found that the wealthiest Americans lived shorter lives than the wealthiest Europeans. In fact, wealthy Northern and Western Europeans had death rates 35 percent lower than the wealthiest Americans, whose lifespans were more like the poorest in Northern and Western Europe -- which includes countries such as France, the Netherlands, and Switzerland. "The findings are a stark reminder that even the wealthiest Americans are not shielded from the systemic issues in the US contributing to lower life expectancy, such as economic inequality or risk factors like stress, diet or environmental hazards," lead study author Irene Papanicolas, a professor of health services, policy and practice at Brown, said in a news release.

The study looked at health and wealth data of more than 73,000 adults across the US and Europe who were 50 to 85 years old in 2010. There were more than 19,000 from the US, nearly 27,000 from Northern and Western Europe, nearly 19,000 from Eastern Europe, and nearly 9,000 from Southern Europe. For each region, participants were divided into wealth quartiles, with the first being the poorest and the fourth being the richest. The researchers then followed participants until 2022, tracking deaths. The US had the largest gap in survival between the poorest and wealthiest quartiles compared to European countries. America's poorest quartile also had the lowest survival rate of all groups, including the poorest quartiles in all three European regions.

While less access to health care and weaker social structures can explain the gap between the wealthy and poor in the US, it doesn't explain the differences between the wealthy in the US and the wealthy in Europe, the researchers note. There may be other systemic factors at play that make Americans uniquely short-lived, such as diet, environment, behaviors, and cultural and social differences. "If we want to improve health in the US, we need to better understand the underlying factors that contribute to these differences -- particularly amongst similar socioeconomic groups -- and why they translate to different health outcomes across nations," Papanicolas said. The findings have been published in the New England Journal of Medicine.

Longtime Slashdot reader backslashdot writes: Commentary, video, and a publication in this week's Nature Neuroscience herald a significant advance in brain-computer interface (BCI) technology, enabling speech by decoding electrical activity in the brain's sensorimotor cortex in real-time. Researchers from UC Berkeley and UCSF employed deep learning recurrent neural network transducer models to decode neural signals in 80-millisecond intervals, generating fluent, intelligible speech tailored to each participant's pre-injury voice. Unlike earlier methods that synthesized speech only after a full sentence was completed, this system can detect and vocalize words within just three seconds. It is accomplished via a 253-electrode array chip implant on the brain. Code and the dataset to replicate the main findings of this study are available in the Chang Lab's public GitHub repository.

Two scientific journals that experimented with paying peer reviewers found the practice sped up the review process without compromising quality, according to findings published this month.

Critical Care Medicine offered $250 to half of 715 invited reviewers, with 53% accepting compared to 48% of unpaid reviewers. Paid reviews were completed one day faster on average. In a more dramatic result, Biology Open saw reviews completed in 4.6 business days when paying reviewers $284 per review, versus 38 days for unpaid reviews. "For the editors it has been extremely helpful because, prior to this, in some areas it was very difficult to secure reviewers," said Alejandra Clark, managing editor of Biology Open.

An anonymous reader quotes a report from MIT Technology Review: The first clinical trial of a therapy bot that uses generative AI suggests it was as effective as human therapy for participants with depression, anxiety, or risk for developing eating disorders. Even so, it doesn't give a go-ahead to the dozens of companies hyping such technologies while operating in a regulatory gray area. A team led by psychiatric researchers and psychologists at the Geisel School of Medicine at Dartmouth College built the tool, called Therabot, and the results were published on March 27 in the New England Journal of Medicine. Many tech companies are building AI therapy bots to address the mental health care gap, offering more frequent and affordable access than traditional therapy. However, challenges persist: poorly worded bot responses can cause harm, and forming meaningful therapeutic relationships is hard to replicate in software. While many bots rely on general internet data, researchers at Dartmouth developed "Therabot" using custom, evidence-based datasets. Here's what they found: To test the bot, the researchers ran an eight-week clinical trial with 210 participants who had symptoms of depression or generalized anxiety disorder or were at high risk for eating disorders. About half had access to Therabot, and a control group did not. Participants responded to prompts from the AI and initiated conversations, averaging about 10 messages per day. Participants with depression experienced a 51% reduction in symptoms, the best result in the study. Those with anxiety experienced a 31% reduction, and those at risk for eating disorders saw a 19% reduction in concerns about body image and weight. These measurements are based on self-reporting through surveys, a method that's not perfect but remains one of the best tools researchers have.

These results ... are about what one finds in randomized control trials of psychotherapy with 16 hours of human-provided treatment, but the Therabot trial accomplished it in about half the time. "I've been working in digital therapeutics for a long time, and I've never seen levels of engagement that are prolonged and sustained at this level," says [Michael Heinz, a research psychiatrist at Dartmouth College and Dartmouth Health and first author of the study].

Stanford University researchers have proposed creating "bodyoids" -- ethically sourced human bodies grown from stem cells without neural components for consciousness or pain sensation -- to revolutionize medical research and address organ shortages. In a new opinion piece published in MIT Technology Review, scientists Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi argue that recent advances in biotechnology make this concept increasingly plausible. The approach would combine pluripotent stem cells, artificial uterus technology, and genetic techniques to inhibit brain development.

The researchers point to persistent shortages of human biological materials as a major bottleneck in medical progress. More than 100,000 patients currently await solid organ transplants in the US alone, while less than 15% of drugs entering clinical trials receive regulatory approval. These lab-grown bodies could potentially generate patient-specific organs that are perfect immunological matches, eliminate the need for lifelong immunosuppression, and provide personalized drug screening models.

Scientists in China successfully transplanted a genetically modified pig liver into a brain-dead patient, where it functioned for 10 days. The liver, modified to reduce immune rejection, produced key proteins and bile, showing compatibility and offering hope for future short-term xenotransplants. The Guardian reports: The surgery, at a Chinese hospital last year, is thought to mark the first time a pig liver has been transplanted into a human. It raises the prospect of pig livers serving as a "bridging organ" for patients on the waiting list for a transplant or to support liver function while their own organ regenerates. [...] The latest procedure was carried out in a 50-year-old man diagnosed with brain death after a severe head injury. The patient's own liver was intact and, in a surgery that took more than 10 hours, the organ taken from a genetically modified Bama miniature pig was plumbed into his blood supply as an additional liver.

The pig had six genetic modifications aimed at preventing immune rejection. These included deactivating genes that contribute to the production of sugars on the surface of pig cells, which the human immune system attacks, and introducing genes that express human proteins to "humanize" the liver. After the transplant, the pig liver showed signs of functioning, including producing bile, which helps break down fats in the digestive system, and porcine albumin, a blood protein. The team behind the advance, described in the journal Nature, said it was not clear whether the liver would have been able to fully support the patient, given that he had an existing liver and because the liver was removed after 10 days at the request of his family.

The United States has won far more Nobel Prizes in physics, chemistry, and medicine than any other nation, with the UK and Germany following in second and third place, according to an analysis of nearly 900 prize-winning publications.

Universities account for roughly three-fourths of Nobel Prize-winning research, with a small number of elite institutions producing a disproportionate share of winners. Cambridge University leads with 32 prizes, followed by Harvard (22) and Columbia (13). While prizes are concentrated among researchers from the US, UK, and Germany, 43 countries have produced at least one scientific Nobel laureate.

Outside Europe and the Anglosphere, Japan leads with 11 prizes, while Argentina, China, and India have only one or two each. The average age of Nobel Prize winners has steadily increased from about 45 in the 1920s to 65 in the 2010s, though the age at which scientists perform their groundbreaking work has remained relatively constant at around 40.

In an op-ed for MIT Technology Review, authors Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi make the case for human "bodyoids" that could reduce animal testing, improve drug development, and alleviate organ shortages: Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation so long? These challenges stem in large part from a common root cause: a severe shortage of ethically sourced human bodies. It may be disturbing to characterize human bodies in such commodifying terms, but the unavoidable reality is that human biological materials are an essential commodity in medicine, and persistent shortages of these materials create a major bottleneck to progress.

This imbalance between supply and demand is the underlying cause of the organ shortage crisis, with more than 100,000 patients currently waiting for a solid organ transplant in the US alone. It also forces us to rely heavily on animals in medical research, a practice that can't replicate major aspects of human physiology and makes it necessary to inflict harm on sentient creatures. In addition, the safety and efficacy of any experimental drug must still be confirmed in clinical trials on living human bodies. These costly trials risk harm to patients, can take a decade or longer to complete, and make it through to approval less than 15% of the time.

There might be a way to get out of this moral and scientific deadlock. Recent advances in biotechnology now provide a pathway to producing living human bodies without the neural components that allow us to think, be aware, or feel pain. Many will find this possibility disturbing, but if researchers and policymakers can find a way to pull these technologies together, we may one day be able to create "spare" bodies, both human and nonhuman. These could revolutionize medical research and drug development, greatly reducing the need for animal testing, rescuing many people from organ transplant lists, and allowing us to produce more effective drugs and treatments. All without crossing most people's ethical lines.

Although it may seem like science fiction, recent technological progress has pushed this concept into the realm of plausibility. Pluripotent stem cells, one of the earliest cell types to form during development, can give rise to every type of cell in the adult body. Recently, researchers have used these stem cells to create structures that seem to mimic the early development of actual human embryos. At the same time, artificial uterus technology is rapidly advancing, and other pathways may be opening to allow for the development of fetuses outside of the body. Such technologies, together with established genetic techniques to inhibit brain development, make it possible to envision the creation of "bodyoids" -- a potentially unlimited source of human bodies, developed entirely outside of a human body from stem cells, that lack sentience or the ability to feel pain.

NPR reports on research "into whether our defenses built up from past flu seasons can offer any protection against H5N1 bird flu." So far, the findings offer some reassurance. Antibodies and other players in the immune system may buffer the worst consequences of bird flu, at least to some degree. "There's certainly preexisting immunity," says Florian Krammer, a virologist at Mount Sinai's Icahn School of Medicine who is involved in some of the new studies. "That's very likely not going to protect us as a population from a new pandemic, but it might give us some protection against severe disease." This protection is based on shared traits between bird flu and types of seasonal flu that have circulated among us. Certain segments of the population, namely older people, may be particularly well-primed because of flu infections during early childhood.

Of course, there are caveats. "While this is a bit of a silver lining, it doesn't mean we should all feel safe," says Seema Lakdawala, a virologist at Emory University's School of Medicine whose lab is probing this question. For one thing, the studies can't be done on people. The conclusions are based on animal models and blood tests that measure the immune response. And how this holds up for an individual is expected to vary considerably, depending on their own immune history, underlying health conditions and other factors. But for now, influenza researchers speculate this may be one reason most people who've caught bird flu over the past year have not fallen severely ill....

Research published this month is encouraging. By analyzing blood samples from close to 160 people, a team at the University of Pennsylvania and the University of Chicago were able to show that people born roughly before 1965 had higher levels of antibodies — proteins that bind to parts of the virus — which cross-react to the current strain of bird flu.
This week U.S. federal officials also "announced funding for avian influenza research projects, including money for new vaccine projects and potential treatments," the Guardian report. The head of America's agriculture department said it would invest $100 million, as part of a larger $1 billion initiative to fight bird flu and stop rising egg prices, according to the nonprofit news site Iowa Capital Dispatch.

A newly FDA-approved form of adaptive deep-brain stimulation (DBS) for Parkinson's disease adjusts electrical stimulation in real time based on an individual's brain signals, improving symptom control and reducing medication dependence. Scientific American: For decades, Keith Krehbiel took high doses of medications with a debilitating side effect -- severe nausea -- following his diagnosis with early-onset Parkinson's disease at age 42 in 1997. When each dose wore off, he experienced dyskinesia -- involuntary, repetitive muscle movements. In his case, this consisted of head bobbing and weaving. Krehbiel is among one million Americans who live with this progressive neurological disorder, which causes slowed movements, tremors and balance problems. But soon after surgery to implant electrodes into specific areas of his brain in 2020, his life dramatically improved. "My tremor went away almost entirely," says Krehbiel, now age 70 and a professor emeritus of political science at the Stanford Graduate School of Business, whose Parkinson's symptoms began at age 40 and were initially misdiagnosed as repetitive stress injury from computer use. "I reduced my Parkinson's meds by more than two thirds," he adds. "And I no longer have a sensation of a foggy brain, nor nausea or dyskinesia."

Krehbiel was the first participant to enroll in a clinical trial testing a new form of deep-brain stimulation (DBS), a technology that gained approval from the U.S. Food and Drug Administration for Parkinson's tremor and essential tremor in 1997 (it was later approved for other symptoms and conditions). The new adaptive system adjusts stimulation levels automatically based on the person's individual brain signals. In late February it received FDA approval for Parkinson's disease "based on results of the international multicenter trial, which involved participants at 10 sites across a total of four countries -- the U.S., the Netherlands, Canada and France. This technology is suitable for anyone with Parkinson's, not just individuals in clinical trials, says Helen Bronte-Stewart, the recent trial's global lead investigator and a neurologist specializing in movement disorders at Stanford Medicine. "Like a cardiac pacemaker that responds to the rhythms of the heart, adaptive deep-brain stimulation uses a person's individual brain signals to control the electric pulses it delivers," Bronte-Stewart says. "This makes it more personalized, precise and efficient than older DBS methods."

"Traditional DBS delivers constant stimulation, which doesn't always match the fluctuating symptoms of Parkinson's disease," adds neurologist Todd Herrington, another of the trial's investigators and director of the deep-brain stimulation program at Massachusetts General Hospital. With adaptive DBS, "the goal is to adjust stimulation in real time to provide more effective symptom control, fewer side effects and improved patient quality of life." Current FDA approval of this adaptive system is for the treatment of Parkinson's only, not essential tremor, dystonia (a neurological disorder that causes excessive, repetitive and involuntary muscle contractions) or epilepsy, which still rely on traditional, continuous DBS, Herrington says.

An anonymous reader quotes a report from 404 Media: Last week, Aix Marseille University, France's largest university, invited American scientists who believe their work is at risk of being censored by Donald Trump administration's anti-science policies to continue their research in France. Today, the university announced that it is already seeing great interest from scientists at NASA, Yale, Stanford, and other American schools and government agencies, and that it wants to expand the program to other schools and European countries to absorb all the researchers who want to leave the United States. "We are witnessing a new brain drain," Eric Berton, Aix Marseille University's president, said in a press release. "We will do everything in our power to help as many scientists as possible continue their research. However, we cannot meet all demands on our own. The Ministry of Education and Research is fully supporting and assisting us in this effort, which is intended to expand at both national and European levels."

The press release from the university claims that researchers from Stanford, Yale, NASA, the National Institute of Health, George Washington University, "and about 15 other prestigious institutions," are now considering "scientific exile." More than 40 American scientists have expressed interest in the program, it said. Their key research areas are "health (LGBT+ medicine, epidemiology, infectious diseases, inequalities, immunology, etc.), environment and climate change (natural disaster management, greenhouse gases, social impact, artificial intelligence), humanities and social sciences (communication, psychology, history, cultural heritage), astrophysics."

"The current Executive Orders have led to a termination of one of my research grants. While it was not a lot of money, it was a high profile, large national study," one researcher who has reached out to Aix Marseille University in order to take advantage of the program told me. 404 Media granted the researcher anonymity because speaking about the program might jeopardize their current position at a leading American university. "While I have not had to lay off staff as a result of that particular cancellation, I will have to lay off staff if additional projects are terminated. Everything I focus on is now a banned word." The program, called "Safe Place for Science," initially will fund 15 researchers with 15 million Euros. Aix Marseille University says that it is already working closely with the regional government and France's Chamber of Commerce and Industry "to facilitate the arrival of these scientists and their families in the region, offering support with employment, housing, school access, transportation, and visas." "We are doing what is necessary to provide them with the best living environment. We are ready to welcome them and will make them true children of the country!" Renaud Muselier, President of the Regional Council of Provence-Alpes-Cote d'Azur, said in a statement.